Ignite Creation Date:
2025-12-25 @ 12:40 AM
Ignite Modification Date:
2025-12-27 @ 5:02 AM
Study NCT ID:
NCT05442567
Status:
RECRUITING
Last Update Posted:
2025-04-09
First Post:
2022-06-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003093', 'term': 'Colitis, Ulcerative'}, {'id': 'D003424', 'term': 'Crohn Disease'}], 'ancestors': [{'id': 'D003092', 'term': 'Colitis'}, {'id': 'D005759', 'term': 'Gastroenteritis'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D015212', 'term': 'Inflammatory Bowel Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C543529', 'term': 'vedolizumab'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 240}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2023-05-16', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-04', 'completionDateStruct': {'date': '2031-08-15', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-04-07', 'studyFirstSubmitDate': '2022-06-30', 'studyFirstSubmitQcDate': '2022-06-30', 'lastUpdatePostDateStruct': {'date': '2025-04-09', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-07-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2031-08-15', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Treatment Cohort: Number of Participants With at Least One Adverse Event (AE)', 'timeFrame': 'From first dose of study drug up to approximately 5 years', 'description': 'An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have causal relationship with this treatment. AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to drug.'}, {'measure': 'Observational Cohort: Number of Participants With Prespecified Safety Events', 'timeFrame': 'Up to approximately 2 years', 'description': 'Prespecified safety events will include serious infections, malignancies, progressive multifocal leukoencephalopathy (PML), concerns about growth and pubertal development, and bowel surgery.'}], 'secondaryOutcomes': [{'measure': 'Treatment Cohort: Time to Major Inflammatory Bowel Disease (IBD)-related Events', 'timeFrame': 'Up to approximately 5 years', 'description': 'Major IBD-related events include hospitalizations, surgeries, and procedures in pediatric participants with UC or CD.'}, {'measure': 'Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Total Score for Participants Aged 9 to 17 Years for Every 24 Weeks', 'timeFrame': 'Baseline, every 24 weeks in this study (up to approximately 5 years)', 'description': "The IMPACT-III questionnaire is a self-reported measure with 35 closed questions encompassing 6 domains: Bowel Symptoms (7 items), Systemic Symptoms (3 items), Social Functioning (12 items), Body Image (3 items), Treatment/Interventions (3 items), and Emotional Functioning (7 items). The IMPACT-III uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The total score is an average of all item scores. The outcome score ranges from 35 to 175, with higher scores suggesting better quality of life. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025."}, {'measure': 'Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Bowel Symptom Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks', 'timeFrame': 'Baseline, every 24 weeks in this study (up to approximately 5 years)', 'description': "The IMPACT-III Bowel Symptom Subscale is a self-reported measure with 7 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The bowel symptom subscale score ranges from 1 to 35, with higher scores indicating lesser bowel symptoms. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025."}, {'measure': 'Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Systemic Symptom Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks', 'timeFrame': 'Baseline, every 24 weeks in this study (up to approximately 5 years)', 'description': "The IMPACT-III Systemic Symptom Subscale is a self-reported measure with 3 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The Systemic symptom subscale score ranges from 1 to 15, with higher scores indicating lesser systemic symptoms. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025."}, {'measure': 'Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Social Functioning Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks', 'timeFrame': 'Baseline, every 24 weeks in this study (up to approximately 5 years)', 'description': "The IMPACT-III Social Functioning Subscale is a self-reported measure with 12 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The social functioning subscale score ranges from 1 to 60, with higher scores indicating better social functioning. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025."}, {'measure': 'Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Body Image Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks', 'timeFrame': 'Baseline, every 24 weeks in this study (up to approximately 5 years)', 'description': "The IMPACT-III Body Image Subscale is a self-reported measure with 3 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The body image subscale score ranges from 1 to 15, with higher scores indicating better body image. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025."}, {'measure': 'Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Treatment/Intervention Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks', 'timeFrame': 'Baseline, every 24 weeks in this study (up to approximately 5 years)', 'description': "The IMPACT-III Treatment/Intervention Subscale is a self-reported measure with 3 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The treatment/intervention subscale score ranges from 1 to 15, with higher scores indicating ease of administration of treatment/interventions. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025."}, {'measure': 'Treatment Cohort: Change From Baseline of Studies MLN0002-3024 (UC) or MLN0002-3025 (CD) in IMPACT-III Emotional Functioning Subscale Score for Participants Aged 9 to 17 Years for Every 24 Weeks', 'timeFrame': 'Baseline, every 24 weeks in this study (up to approximately 5 years)', 'description': "The IMPACT-III Emotional Functioning Subscale is a self-reported measure with 7 closed questions. It uses a 5-point Likert scale ranging from 1 (bad 'quality of life' condition) to 5 (good 'quality of life' condition) for all answers. The emotional functioning subscale score ranges from 1 to 35, with higher scores indicating better emotional functioning. This outcome will be assessed in participants who were aged 9 to 17 years at the time of first dose of study drug in study MLN0002-3024 or MLN0002-3025. Baseline refers to the Baseline of study MLN0002-3024 or MLN0002-3025."}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Drug Therapy'], 'conditions': ['Ulcerative Colitis', "Crohn's Disease"]}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://clinicaltrials.takeda.com/study-detail/ef380ef1e1ac489a?idFilter=%5B%22MLN0002-3029%22%5D', 'label': 'To obtain more information about this study, click this link.'}]}, 'descriptionModule': {'briefSummary': 'The study is an extension of two parent studies (MLN0002-3024 \\[NCT04779307\\] and MLN0002-3025 \\[NCT04779320\\]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.', 'detailedDescription': "This multi-center trial is conducted worldwide. Up to 240 patients would be enrolled from Studies MLN0002-3024 \\[participants with UC\\] and MLN0002-3025 \\[participants with CD\\], either in the Treatment Cohort or in the Observational Cohort. Approximately 93 participants who have previously participated either in study MLN0002-3024 or MLN0002-3025, referred to as parent study, are expected to roll over to the MLN0002-3029 study in the treatment cohort.\n\nTreatment Cohort:\n\nThe drug being tested in this study is called vedolizumab, being studied to treat pediatric patients who have UC or CD.\n\nParticipants eligible for the Treatment Cohort can be administered vedolizumab intravenous (IV) at Week 54 visit of parent study or up to 1 week after Week 54 of the parent study based on the availability of test results needed to assess eligibility of the participant. At this study entry, participants will be administered the same blinded dose of vedolizumab IV that was received at Week 46 in the parent study and will then continue to receive vedolizumab IV at a frequency of once every 8 weeks (Q8W) in the following treatment groups:\n\n* Participants 10 to ≤15 kilogram (kg), Vedolizumab 150 milligram (mg) (High dose)\n* Participants 10 to ≤15 kg, Vedolizumab 100 mg (Low dose)\n* Participants \\>15 to \\<30 kg, Vedolizumab 200 mg (High dose)\n* Participants \\>15 to \\<30 kg, Vedolizumab 100 mg (Low dose)\n* Participants ≥30 kg, Vedolizumab 300 mg (High dose)\n* Participants ≥30 kg, Vedolizumab 150 mg (Low dose)\n\nBlinding of dose group assignment of the parent study will continue until the respective parent study is unblinded in order to protect the blinding of the parent study.\n\nThe overall time to participate in the Treatment Cohort of this study is up to participant withdrawal, or until vedolizumab IV is commercially available for pediatric indication(s) in the participant's country or until other drug access programs become available, or Sponsor's decision for study closure, or for up to approximately 5 years, whichever comes first. Participants who complete or are discontinued from the study for any reason will complete the final safety/end of study (EOS) visit 18 weeks after their last dose of study drug.\n\nObservational Cohort:\n\nParticipants who received at least 1 dose of study drug during parent study and early terminated or are not eligible for the Treatment Cohort of this study after completion of the Week 54 visit of parent study, will be enrolled in the Observational Cohort of this study as part of a long-term follow-up period to assess prespecified safety events of interest and will not receive continued treatment with vedolizumab IV.\n\nThe overall time to participate in the Observational Cohort is up to approximately 2 years."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '2 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Main Inclusion Criteria:\n\nFor Treatment Cohort:\n\n1. The participant should have completed Study MLN0002-3024 or Study MLN0002-3025 and achieved corticosteroid-free clinical response at Week 54 (and has tapered off of steroids, as applicable, at least 12 weeks before Week 54) as defined by a reduction of partial Mayo score of ≥2 points and ≥25% from baseline for participants with UC, or by a decrease of pediatric Crohn's disease activity index (PCDAI) of ≥15 points for participants with CD and with total PCDAI ≤30.\n2. A male participant who is sexually active with a female partner of childbearing potential agrees to use a barrier method of contraception (e.g., condom with or without spermicide) from signing of participant/parental informed consent and/or pediatric assent throughout the duration of the study and for 18 weeks after last dose. The female partner of a male participant should also be advised to use a highly effective method of contraception.\n3. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use a highly effective method of contraception from signing of participant/parental informed consent and/or pediatric assent throughout the duration of the study and 18 weeks after the last dose.\n\nFor Observational Cohort:\n\n1\\. The participant has received at least 1 dose of vedolizumab during Study MLN0002-3024 or Study MLN0002-3025 and early terminated OR completed the Week 54 visit of Study MLN0002-3024 or Study MLN0002-3025 but was not eligible to enroll in the treatment cohort of this study.\n\nMain Exclusion Criteria:\n\nFor Treatment Cohort only:\n\n1. The participant currently requires major surgical intervention for UC or CD (e.g., bowel resection), or is anticipated to require major surgical intervention for UC or CD during the study.\n2. The participant has developed any new unstable or uncontrolled cardiovascular, heart failure moderate to severe (New York Class Association III or IV), pulmonary, hepatic, renal, gastrointestinal (GI), genitourinary, hematological, coagulation, immunological, endocrine/metabolic, neurological, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise participant safety.\n3. The participant has other serious comorbidities that will limit their ability to complete the study.\n4. The participant is unable to comply with all study assessments.\n5. The participant has hypersensitivity or allergies to any of the vedolizumab excipients.\n6. The participant is lactating or pregnant."}, 'identificationModule': {'nctId': 'NCT05442567', 'briefTitle': "A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)", 'organization': {'class': 'INDUSTRY', 'fullName': 'Takeda'}, 'officialTitle': "A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Intravenous in Pediatric Patients With Ulcerative Colitis or Crohn's Disease", 'orgStudyIdInfo': {'id': 'MLN0002-3029'}, 'secondaryIdInfos': [{'id': '2023-509046-36-00', 'type': 'CTIS', 'domain': 'EU CT Number'}, {'id': 'jRCT2071230036', 'type': 'REGISTRY', 'domain': 'jRCT'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 150 mg', 'description': 'Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing 10 to ≤15 kg will receive vedolizumab 150 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.', 'interventionNames': ['Drug: Vedolizumab IV']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 100 mg', 'description': 'Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing 10 to ≤15 kg will receive vedolizumab 100 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.', 'interventionNames': ['Drug: Vedolizumab IV']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 200 mg', 'description': 'Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing \\>15 to \\<30 kg will receive vedolizumab 200 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.', 'interventionNames': ['Drug: Vedolizumab IV']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 100 mg', 'description': 'Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing \\>15 to \\<30 kg will receive vedolizumab 100 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.', 'interventionNames': ['Drug: Vedolizumab IV']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment Cohort: Participants ≥30 kg, Vedolizumab 300 mg', 'description': 'Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing ≥30 kg will receive vedolizumab 300 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.', 'interventionNames': ['Drug: Vedolizumab IV']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment Cohort: Participants ≥30 kg, Vedolizumab 150 mg', 'description': 'Eligible participants from studies MLN0002-3024 or MLN0002-3025 weighing ≥30 kg will receive vedolizumab 150 mg, IV infusion, Q8W, (same as their Week 46 dose in parent study) in this study for up to approximately 5 years.', 'interventionNames': ['Drug: Vedolizumab IV']}, {'type': 'OTHER', 'label': 'Observational Cohort: Early Terminated Participants From Parent Studies', 'description': 'Participants will have assessment visits at Day 1 and Weeks 8, 34, 60, and 86 as part of a long-term follow-up period to assess prespecified safety events of interest and to monitor growth and pubertal development for approximately 2 years after their last dose of study drug in parent study.', 'interventionNames': ['Other: No Intervention']}], 'interventions': [{'name': 'Vedolizumab IV', 'type': 'DRUG', 'otherNames': ['MLN0002', 'ENTYVIO', 'KYNTELES'], 'description': 'Vedolizumab IV infusion', 'armGroupLabels': ['Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 100 mg', 'Treatment Cohort: Participants 10 to ≤15 kg, Vedolizumab 150 mg', 'Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 100 mg', 'Treatment Cohort: Participants >15 to <30 kg, Vedolizumab 200 mg', 'Treatment Cohort: Participants ≥30 kg, Vedolizumab 150 mg', 'Treatment Cohort: Participants ≥30 kg, Vedolizumab 300 mg']}, {'name': 'No Intervention', 'type': 'OTHER', 'description': 'Participants will not receive any intervention in the Observational Cohort.', 'armGroupLabels': ['Observational Cohort: Early Terminated Participants From Parent Studies']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85016-7710', 'city': 'Phoenix', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'apatel12@phoenixchildrens.com', 'phone': '602-933-0940'}, {'name': 'Ashish Patel', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Phoenix Childrens Hospital -1919 E Thompson Rd', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '92123-4223', 'city': 'San Diego', 'state': 'California', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'yhuang815@163.com', 'phone': '381-688-2247', 'phoneExt': '+861'}, {'name': 'Ying Huang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Rady Childrens Hospital San Diego - PIN', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '30342', 'city': 'Atlanta', 'state': 'Georgia', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'shlomico@tlvmc.gov.il', 'phone': '252-426-6988', 'phoneExt': '+97'}, {'name': 'Shlomi Cohen', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Childrens Center For Digestive Healthcare', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '60068', 'city': 'Park Ridge', 'state': 'Illinois', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'Ts.Gunasekaran@aah.org', 'phone': '847-723-7700'}, {'name': 'Thirumazhisai S. Gunasekaran', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Advocate Children's Hospital Park Ridge", 'geoPoint': {'lat': 42.01114, 'lon': -87.84062}}, {'zip': '21287-0005', 'city': 'Baltimore', 'state': 'Maryland', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'moliva@jhmi.edu', 'phone': '141-095-5876', 'phoneExt': '9'}, {'name': 'Maria Oliva-Hemker', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Johns Hopkins University', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '02115-5724', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'naamah.zitomersky@childrens.harvard.edu', 'phone': '617-355-2962'}, {'name': 'Naamah Zitomersky', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Boston Children's Hospital", 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '55413', 'city': 'Minneapolis', 'state': 'Minnesota', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'Ramalingam.Arumugam@mngi.com', 'phone': '612-813-7240'}, {'name': 'Ramalingam Arumugam', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'MNGI Digestive Health PA-Plymouth', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'zip': '55905-0001', 'city': 'Rochester', 'state': 'Minnesota', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'stephens.michael@mayo.edu', 'phone': '507-266-0114'}, {'name': 'Michael Stephens', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Mayo Clinic - PIN', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'zip': '07960-6136', 'city': 'Morristown', 'state': 'New Jersey', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'joel.rosh@atlantichealth.org', 'phone': '973-971-5676'}, {'name': 'Joel Rosh', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Goryeb Children's Hospital", 'geoPoint': {'lat': 40.79677, 'lon': -74.48154}}, {'zip': '11042-2062', 'city': 'New Hyde Park', 'state': 'New York', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'jmarkowi2@nshs.edu', 'phone': '516-472-3650'}, {'name': 'James Markowitz', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'The Steven and Alexandra Cohen Childrens Medical Center of New York - BRANY - PPDS', 'geoPoint': {'lat': 40.7351, 'lon': -73.68791}}, {'zip': '44106-1716', 'city': 'Cleveland', 'state': 'Ohio', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'jonathan.moses@uhhospitals.org', 'phone': '216-844-1765'}, {'name': 'Jonathan Moses', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University Hospitals Cleveland Medical Center', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '15201', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'whitney.sunseri@chp.edu', 'phone': '412-692-6558'}, {'name': 'Whitney Sunseri', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital of Pittsburgh", 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'faith.ihekweazu@bcm.edu', 'phone': '832-824-1000'}, {'name': 'Faith Ihekweazu', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Texas Children's Hospital", 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '24018-0720', 'city': 'Roanoke', 'state': 'Virginia', 'status': 'NOT_YET_RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'jcolazagasti@carilionclinic.org', 'phone': '540-985-9832'}, {'name': 'Juan Olazagasti', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Carilion Children's Tanglewood Center", 'geoPoint': {'lat': 37.27097, 'lon': -79.94143}}, {'zip': '2145', 'city': 'Westmead', 'state': 'New South Wales', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'shoma.dutt@health.nsw.gov.au', 'phone': '+61298453999'}, {'name': 'Shoma Dutt', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital at Westmead", 'geoPoint': {'lat': -33.80383, 'lon': 150.98768}}, {'zip': '4101', 'city': 'South Brisbane', 'state': 'Queensland', 'status': 'NOT_YET_RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'peter.lewindon@health.qld.gov.au', 'phone': '+61730684502'}, {'name': 'Peter Lewindon', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Queensland Childrens Hospital', 'geoPoint': {'lat': -27.48034, 'lon': 153.02049}}, {'zip': '3168', 'city': 'Clayton', 'state': 'Victoria', 'status': 'NOT_YET_RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'Gregory.moore@monash.edu', 'phone': '+61395943177'}, {'name': 'Gregory Moore', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Monash Health, Monash Medical Centre', 'geoPoint': {'lat': -37.91667, 'lon': 145.11667}}, {'zip': '3052', 'city': 'Parkville', 'state': 'Victoria', 'status': 'RECRUITING', 'country': 'Australia', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'george.alex@rch.org.au', 'phone': '61393455060'}, {'name': 'George Alex', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Royal Children's Hospital Melbourne - PIN", 'geoPoint': {'lat': -37.78333, 'lon': 144.95}}, {'zip': '2650', 'city': 'Edegem', 'state': 'Antwerpen', 'status': 'NOT_YET_RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'els.vandevijver@uza.be', 'phone': '+3238213810'}, {'name': 'Els Van de Vijver', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UZ Antwerpen', 'geoPoint': {'lat': 51.15662, 'lon': 4.44504}}, {'zip': '1090', 'city': 'Jette', 'state': 'Brussels Capital', 'status': 'NOT_YET_RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'elisabeth.degreef@uzbrussel.be', 'phone': '+32485022839'}, {'name': 'Elisabeth De Greef', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Universitair Ziekenhuis Brussel - PIN', 'geoPoint': {'lat': 50.87309, 'lon': 4.33419}}, {'zip': '3000', 'city': 'Leuven', 'state': 'Vlaams Brabant', 'status': 'RECRUITING', 'country': 'Belgium', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'ilse.hoffman@uzleuven.be', 'phone': '+3216343843'}, {'name': 'Ilse Hoffman', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UZ Leuven', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': 'AB T6G 2B7', 'city': 'Edmonton', 'state': 'Alberta', 'status': 'NOT_YET_RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'hien.huynh@ualberta.ca', 'phone': '(780) 248-5420'}, {'name': 'Hien Huynh', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Alberta Hospital', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'zip': 'V6H3V4', 'city': 'Vancouver', 'state': 'British Columbia', 'status': 'NOT_YET_RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'kjacobson@cw.bc.ca', 'phone': '(604) 377-1831'}, {'name': 'Kevan Jacobson', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "British Columbia Children's Hospital", 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'zip': 'N6A 4G5', 'city': 'London', 'state': 'Ontario', 'status': 'NOT_YET_RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'kevin.bax@lhsc.on.ca', 'phone': '(519) 685-8500 x56836'}, {'name': 'Kevin Bax', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'London Health Sciences Centre', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'zip': '100045', 'city': 'Beijing', 'state': 'Beijing Municipality', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'wujiedoc@163.com', 'phone': '+8618940251108'}, {'name': 'Jie Wu', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Beijing Children Hospital,Capital Medical University', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '450000', 'city': 'Zhengzhou', 'state': 'Henan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'lixiaoqinys@126.com', 'phone': '+8615890105818'}, {'name': 'Xiaoqin Li', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Henan Children's Hospital (Zhengzhou Children's Hospital)", 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '201102', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'yhuang815@163.com', 'phone': '+8613816882247'}, {'name': 'Ying Huang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Children's Hospital of Fudan University", 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '310003', 'city': 'Hangzhou', 'state': 'Zhejiang', 'status': 'NOT_YET_RECRUITING', 'country': 'China', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'hzcjie@163.com', 'phone': '+8613858032920'}, {'name': 'Jie Chen', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "The Children's Hospital Zhejiang UniversitySchool of Medicine", 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '10000', 'city': 'Zagreb', 'state': 'City of Zagreb', 'status': 'RECRUITING', 'country': 'Croatia', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'ivahojsak@gmail.com', 'phone': '+38514600291'}, {'name': 'Iva Hojsak', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Klinika Za Djecje Bolesti Zagreb', 'geoPoint': {'lat': 45.81444, 'lon': 15.97798}}, {'zip': '124 62', 'city': 'Athens', 'state': 'Attica', 'status': 'NOT_YET_RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'vpapaev@gmail.com', 'phone': '+302105832228'}, {'name': 'Vassiliki Papaevangelou', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Attikon University General Hospital', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'city': 'Athens', 'status': 'NOT_YET_RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'a.papadopoulou@paidon-agiasofia.gr', 'phone': '+302107467359'}, {'name': 'Alexandra Papadopoulou', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Children\'s Hospital "Agia Sofia"', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '546 42', 'city': 'Thessaloniki', 'status': 'RECRUITING', 'country': 'Greece', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'xinias@email.com', 'phone': '+302310992877'}, {'name': 'Ioannis Xinias', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Ippokratio General Hospital of Thessaloniki', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'zip': '3526', 'city': 'Miskolc', 'state': 'Borsod-Abauj Zemplen county', 'status': 'NOT_YET_RECRUITING', 'country': 'Hungary', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'szakos.iiigyek@bazmkorhaz.hu', 'phone': '+3646515200'}, {'name': 'Erzsebet Szakos', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktato Korhaz', 'geoPoint': {'lat': 48.10327, 'lon': 20.77806}}, {'zip': '1085', 'city': 'Budapest', 'status': 'RECRUITING', 'country': 'Hungary', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'cseharon@gmail.com', 'phone': '+36208258186'}, {'name': 'Aron Cseh', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Semmelweis Egyetem', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '49202', 'city': 'Petah Tikva', 'state': 'Central District', 'status': 'NOT_YET_RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'raanan@shamirmd.com', 'phone': '+97239253672'}, {'name': 'Raanan Shamir', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Schneider Childrens Medical Center of Israel Petah Tikvah PIN', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'zip': '91120', 'city': 'Jerusalem', 'state': 'Jerusalem', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'zevd@hadassah.org.il', 'phone': '+972586645719'}, {'name': 'Zev Davidovics', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hadassah Medical Center - PPDS', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '31096', 'city': 'Haifa', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'r_shaoul@rambam.health.gov.il', 'phone': '+97248543388'}, {'name': 'Ron Shaoul', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Rambam Medical Center - PPDS', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '34362', 'city': 'Haifa', 'status': 'NOT_YET_RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'corinah@clalit.org.il', 'phone': '+4056303'}, {'name': 'Corina Hartman', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Carmel Medical Center', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '91031', 'city': 'Jerusalem', 'status': 'NOT_YET_RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'turnerd@szmc.org.il', 'phone': '+97226666482'}, {'name': 'Dan Turner', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Shaare Zedek Medical Center', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '64239', 'city': 'Tel Aviv', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'shlomico@tlvmc.gov.il', 'phone': '+972524266988'}, {'name': 'Shlomi Cohen', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Tel Aviv Sourasky Medical Center PPDS', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'zip': '80131', 'city': 'Napoli', 'state': 'Campania', 'status': 'NOT_YET_RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'caterina.strisciuglio@unicampania.it', 'phone': '+390815665464'}, {'name': 'Caterina Strisciuglio', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "AOU dell'Universita degli Studi della Campania Luigi Vanvitelli", 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'zip': '80131', 'city': 'Napoli', 'state': 'Campania', 'status': 'NOT_YET_RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'erasmo.miele@unina.it', 'phone': '+390817464565'}, {'name': 'Erasmo Miele', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Azienda Ospedaliera Universitaria Federico II', 'geoPoint': {'lat': 40.87618, 'lon': 14.5195}}, {'zip': '40133', 'city': 'Bologna', 'state': 'Emilia-Romagna', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'patrizia.alvisi@ausl.bologna.it', 'phone': '+390516478437'}, {'name': 'Patrizia Alvisi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Azienda USL di Bologna', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'zip': '161', 'city': 'Rome', 'state': 'Lazio', 'status': 'NOT_YET_RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'marina.aloi@gmail.com', 'phone': '+390649979387'}, {'name': 'Marina Aloi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Sapienza University of Rome', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '20900', 'city': 'Monza', 'state': 'Lombardy', 'status': 'RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'roberto.panceri@irccs-sangerardo.it', 'phone': '+398888888888'}, {'name': 'Roberto Panceri', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Fondazione IRCCS San Gerardo dei Tintori - ASST di Monza A. O. San Gerardo', 'geoPoint': {'lat': 45.58005, 'lon': 9.27246}}, {'zip': '35122', 'city': 'Padua', 'state': 'Veneto', 'status': 'NOT_YET_RECRUITING', 'country': 'Italy', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'maracananzi@yahoo.com', 'phone': '+390498213517'}, {'name': 'Mara Cananzi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Universita degli Studi di Padova', 'geoPoint': {'lat': 45.40797, 'lon': 11.88586}}, {'zip': '830-0011', 'city': 'Kurume-Shi', 'state': 'Hukuoka', 'status': 'NOT_YET_RECRUITING', 'country': 'Japan', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'mizuochi_tatsuki@kurume-u.ac.jp', 'phone': '+81942353311'}, {'name': 'Tatsuki Mizuochi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Kurume University Hospital'}, {'zip': '861-8520', 'city': 'Kumamoto', 'state': 'Kumamoto', 'status': 'NOT_YET_RECRUITING', 'country': 'Japan', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'tturmso@yahoo.co.jp', 'phone': '+81963842111'}, {'name': 'Yugo Takaki', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Japanese Red Cross Kumamoto Hospital', 'geoPoint': {'lat': 32.80589, 'lon': 130.69181}}, {'zip': '113-8431', 'city': 'Bunkyo-Ku', 'state': 'Tokyo', 'status': 'NOT_YET_RECRUITING', 'country': 'Japan', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 't-kudo@juntendo.ac.jp', 'phone': '+81338133111'}, {'name': 'Takahiro Kudo', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Juntendo University Hospital'}, {'zip': '157-8535', 'city': 'Setagaya-Ku', 'state': 'Tokyo', 'status': 'NOT_YET_RECRUITING', 'country': 'Japan', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'arai-k@ncchd.go.jp', 'phone': '+81334160181'}, {'name': 'Katsuhiro Arai', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'National Center for Child Health and Development'}, {'zip': '30-663', 'city': 'Krakow', 'state': 'Lesser Poland Voivodeship', 'status': 'NOT_YET_RECRUITING', 'country': 'Poland', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'kingakd@mp.pl', 'phone': '+48123339330'}, {'name': 'Kinga Kowalska-Duplaga', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Uniwersytecki Szpital Dzieciecy', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '00-728', 'city': 'Warsaw', 'state': 'Masovian Voivodeship', 'status': 'NOT_YET_RECRUITING', 'country': 'Poland', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'm.meglicka@wip.waw.pl', 'phone': '+48226580456'}, {'name': 'Monika Meglicka', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'WIP Warsaw IBD Point Profesor Kierkus', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '04-736', 'city': 'Warsaw', 'state': 'Masovian Voivodeship', 'status': 'NOT_YET_RECRUITING', 'country': 'Poland', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'J.KIERKUS@IPCZD.PL', 'phone': '+486002111648'}, {'name': 'Jaroslaw Kierkus', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Instytut Pomnik Centrum Zdrowia Dziecka', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '35-302', 'city': 'Rzeszów', 'state': 'Podkarpackie Voivodeship', 'status': 'NOT_YET_RECRUITING', 'country': 'Poland', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'korczowski@op.pl', 'phone': '+48177404065'}, {'name': 'Bartosz Korczowski', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Korczowski Bartosz, Gabinet Lekarski', 'geoPoint': {'lat': 50.04132, 'lon': 21.99901}}, {'zip': '40-752', 'city': 'Katowice', 'state': 'Silesian Voivodeship', 'status': 'NOT_YET_RECRUITING', 'country': 'Poland', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'urszulachlebowczyk@wp.pl', 'phone': '+48322071700'}, {'name': 'Urszula Grzybowska-Chlebowczyk', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Gornoslaskie Centrum Zdrowia Dziecka Im. Sw. Jana Pawla II Spsk Nr 6 Sum W Katowicach', 'geoPoint': {'lat': 50.2597, 'lon': 19.02173}}, {'zip': '71-434', 'city': 'Szczecin', 'state': 'West Pomeranian Voivodeship', 'status': 'RECRUITING', 'country': 'Poland', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'gawdis@twojaprzychodnia.com', 'phone': '+48914332919'}, {'name': 'Beata Gawdis-Wojnarska', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Twoja Przychodnia SCM', 'geoPoint': {'lat': 53.42894, 'lon': 14.55302}}, {'zip': '91-738', 'city': 'Lodz', 'status': 'NOT_YET_RECRUITING', 'country': 'Poland', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'ewa.toporowska-kowalska@umed.lodz.pl', 'phone': '+48426177792'}, {'name': 'Ewa Toporowska-Kowalska', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'SPZOZ Centralny Szpital Kliniczny UM w Lodzi', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '93-338', 'city': 'Lodz', 'state': 'Łódź Voivodeship', 'status': 'NOT_YET_RECRUITING', 'country': 'Poland', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'elcia@friend.pl', 'phone': '+48422711341'}, {'name': 'Elzbieta Czkwianianc', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Instytut Centrum Zdrowia Matki Polki', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '833 40', 'city': 'Bratislava', 'status': 'NOT_YET_RECRUITING', 'country': 'Slovakia', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'iicierna@gmail.com', 'phone': '+421259371240'}, {'name': 'Iveta Cierna', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Narodny ustav detskych chorob', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'zip': '41404', 'city': 'Daegu', 'state': "Daegu Gwang'yeogsi", 'status': 'NOT_YET_RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'benkang@knu.ac.kr', 'phone': '+82532003780'}, {'name': 'Ben Kang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Kyungpook National University Chilgok hospital', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}, {'zip': '21565', 'city': 'Incheon', 'state': "Incheon Gwang'yeogsi", 'status': 'NOT_YET_RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'ryoo518@gilhospital.com', 'phone': '+82324603213'}, {'name': 'Eell Ryoo', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Gachon University Gil Medical Center', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}, {'zip': '03080', 'city': 'Seoul', 'status': 'NOT_YET_RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'mjschj@snu.ac.kr'}, {'name': 'Jin Soo Moon', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '6351', 'city': 'Seoul', 'status': 'NOT_YET_RECRUITING', 'country': 'South Korea', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'smc_yhc@naver.com', 'phone': '+82234103901'}, {'name': 'Yon-Ho Choe', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Samsung Medical Center - PPDS', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': 'WC1N 3AJ', 'city': 'London', 'state': 'London, City of', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'kelsey.jones@gosh.nhs.uk', 'phone': '+447779142231'}, {'name': 'Kelsey Jones', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Great Ormond Street Hospital (GOSH)', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'CF14 4XW', 'city': 'Cardiff', 'state': 'South Glamorgan', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'amar.wahid@wales.nhs.uk', 'phone': '+448888888888'}, {'name': 'Amar Wahid', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Noahs Ark Childrens Hospital for Wales - PPDS - PIN', 'geoPoint': {'lat': 51.48, 'lon': -3.18}}, {'zip': 'B4 6NH', 'city': 'Birmingham', 'state': 'West Midlands', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'rafeeq.muhammed@nhs.net', 'phone': '+4401213338705'}, {'name': 'Rafeeq Muhammed', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Birmingham Children's Hospital NHS Foundation Trust", 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'E1 1BB', 'city': 'London', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'marco.gasparetto@nhs.net', 'phone': '+448888888888'}, {'name': 'Marco Gasparetto', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Barts Health NHS Trust', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'M27 4HA', 'city': 'Manchester', 'status': 'NOT_YET_RECRUITING', 'country': 'United Kingdom', 'contacts': [{'name': 'Site Contact', 'role': 'CONTACT', 'email': 'andrew.fagbemi@mft.nhs.uk', 'phone': '+441617012371'}, {'name': 'Andrew (Sunday) Fagbemi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Royal Manchester Children's Hospital - PPDS", 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}], 'centralContacts': [{'name': 'Takeda Contact', 'role': 'CONTACT', 'email': 'medinfoUS@takeda.com', 'phone': '+1-877-825-3327'}], 'overallOfficials': [{'name': 'Study Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Takeda'}]}, 'ipdSharingStatementModule': {'url': 'https://vivli.org/ourmember/takeda/', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'], 'ipdSharing': 'YES', 'description': "Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.", 'accessCriteria': 'IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Takeda', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}